Danaher Corp Dossier
Outlook & Key Dates
Estimates, guidance, catalysts, and upcoming events
Analyst Estimates Learn more →
5-Yr Fwd EPS Growth
9.4%projected annual EPS growth
Analyst Coverage
23analysts covering
FY Revenue (est.)
$26.3Bnext fiscal year
FY EPS (est.)
$8.51next fiscal year
Reporting Calendar
| Event | Expected Date |
|---|---|
| Q3 2026 Earnings Release | 20 Oct 2026 |
Monitoring Framework
Key Performance Indicators
Bioprocessing Equipment Orders Growth (YoY) Quarterly15.0%Target: Positive year-over-year growth
Non-GAAP Core Revenue Growth Quarterly3.0%Target: 3 to 4%
Non-GAAP Core Revenue Growth Excluding Respiratory Testing Quarterly4.5%
Watch Items
- Bioprocessing Revenue Project-Timing ShiftsTrigger: Over $100 million in revenue delayed or shifted into 2027Action: Monitor customer readiness and project execution timelines to ensure delayed revenue is recognized in 2027.
- China Diagnostics Policy HeadwindsTrigger: Volume-based procurement (VBP) and reimbursement impacts exceeding expectationsAction: Maintain active dialogue with the Chinese government and adjust commercial strategies to mitigate margin pressure.
- Masimo Integration and Synergy RealizationTrigger: Adjusted EPS accretion below $0.15 to $0.20 in the first full year post-closeAction: Track integration milestones, cost synergies, and expansion of the patient-monitoring business into acute bedside care.
Research as of 2 Sep 2026